A detailed history of Tekla Capital Management LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 67,506 shares of XENE stock, worth $2.63 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
67,506
Previous 83,714 19.36%
Holding current value
$2.63 Million
Previous $3 Million 13.28%
% of portfolio
0.1%
Previous 0.11%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

SELL
$34.84 - $43.54 $564,686 - $705,696
-16,208 Reduced 19.36%
67,506 $2.6 Million
Q4 2022

Feb 10, 2023

BUY
$33.06 - $39.43 $726,691 - $866,710
21,981 Added 35.61%
83,714 $3.3 Million
Q3 2022

Nov 01, 2022

BUY
$30.79 - $39.82 $985,988 - $1.28 Million
32,023 Added 107.79%
61,733 $2.23 Million
Q2 2022

Jul 29, 2022

BUY
$25.44 - $35.16 $755,822 - $1.04 Million
29,710 New
29,710 $904,000
Q4 2021

Feb 14, 2022

SELL
$15.6 - $35.4 $2.64 Million - $5.98 Million
-169,030 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$16.81 - $20.0 $52,648 - $62,640
3,132 Added 1.89%
169,030 $3.15 Million
Q1 2021

May 14, 2021

BUY
$13.65 - $21.31 $2.26 Million - $3.54 Million
165,898 New
165,898 $2.97 Million
Q1 2020

May 14, 2020

SELL
$8.08 - $17.57 $783,444 - $1.7 Million
-96,961 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$8.11 - $14.65 $786,353 - $1.42 Million
96,961 New
96,961 $1.27 Million
Q3 2018

Nov 13, 2018

SELL
$9.0 - $14.9 $1.47 Million - $2.44 Million
-163,819 Closed
0 $0
Q2 2018

Aug 13, 2018

SELL
$4.8 - $9.2 $557,668 - $1.07 Million
-116,181 Reduced 41.49%
163,819 $1.51 Million
Q1 2018

May 14, 2018

SELL
$2.7 - $4.9 $189,000 - $343,000
-70,000 Reduced 20.0%
280,000 $1.37 Million
Q2 2017

Aug 14, 2017

BUY
N/A
350,000
350,000 $1.1 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.43B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.